Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
Glaucoma: Pathophysiology, Treatment and Progression
share announcement

Glaucoma: Pathophysiology, Treatment and Progression

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: closed (20 December 2022) | Viewed by 3793

Special Issue Editors

Dr. Anna Bassi

E-Mail Website
Guest Editor
Department of Experimental Medicine (DIMES), University of Genoa, 16132 Genoa, Italy
Interests: in vitro models; hiPSC; 3D culture; millifluidic culture systems; molecular pathways
Special Issues, Collections and Topics in MDPI journals
Dr. Stefania Vernazza

E-Mail
Guest Editor
Department of Experimental Medicine (DIMES), University of Genoa, 16132 Genoa, Italy
Interests: in vitro models; hiPSC; 3D culture; millifluidic culture systems
Special Issues, Collections and Topics in MDPI journals
Dr. Sara Tirendi

E-Mail Website
Guest Editor
Department of Experimental Medicine, General Pathology, University of Genoa, Genoa, Italy
Interests: 3D in vitro models; millifluidics; glaucoma,trabecular meshwork; retinal ganglion cells; inflammatory markers; apoptosis; oxidative stress; cell imaging

Special Issue Information

Dear Colleagues,

Glaucoma remains one of the main cause of ocular morbidity worldwide, whose onset is promoted by a series of risk factors while its course includes different alteration pathways culminating with loss of sight. Although intraocular pressure (IOP) is the main “druggable” target, it is been well established that intervene only on it is really not enough to prevent the retinal ganglion cell (RGC) loss. In this regard, neuroprotection is one of the most promising approaches for hampering the RGC degeneration.

The present Special Issue, edited by Dr. Anna Maria Bassi, Dr. Stefania Vernazza and Dr. Sara Tirendi, will collect original research articles (i.e., basic science and clinical research) and review based on glaucoma risk factors and degeneration mechanisms as well as the latest updates on diagnostic modalities and therapeutic options aimed at sight preservation

Dr. Anna Maria Bassi
Dr. Stefania Vernazza
Dr. Sara Tirendi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glaucoma
  • risk factors
  • neuroprotection
  • new targeted therapy
  • RGC degeneration
  • diagnostic markers

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 662 KiB  
Article
Micropulse Laser Trabeculoplasty with 577 nm Wavelength at 1500 or 1000 mW for Primary Open-Angle Glaucoma: A Pilot Study
by Tommaso Verdina, Matteo Gironi, Bruno Battaglia, Michele Gentile, Johanna Chester, Shaniko Kaleci, Gianluca Scatigna, Rodolfo Mastropasqua and Gian Maria Cavallini
Life 2023, 13(4), 982; https://doi.org/10.3390/life13040982 - 10 Apr 2023
Viewed by 1466
Abstract
Aim: To investigate the efficacy and safety of micropulse laser trabeculoplasty (MLT) using a 577 nm yellow wavelength laser randomly assigned to either 1500 or 1000 mW in patients with primary open-angle glaucoma (POAG). Methods: A prospective, double-blinded study of POAG [...] Read more.
Aim: To investigate the efficacy and safety of micropulse laser trabeculoplasty (MLT) using a 577 nm yellow wavelength laser randomly assigned to either 1500 or 1000 mW in patients with primary open-angle glaucoma (POAG). Methods: A prospective, double-blinded study of POAG patients was performed in a single center. MLT treatment included a 577 nm micropulse laser (IRIDEX IQ 577TM, IRIDEX, Mountain View, CA, USA) to 360° of the trabecular meshwork at randomly assigned varying powers: 1500 mW in one eye (MLT 1500 group) and 1000 mW in the other (MLT 1000 group). Best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal central thickness (CCT), and endothelial cell count (ECC) were evaluated at baseline (T0), post-operative 1 h (T1), 24 h (T2), 1 month (T3), 3 months (T4), and 6 months (T5) after laser treatment. Topical medications were assessed pre-treatment and at T4. Results: Among the 18 eyes included, we achieved a success rate (IOP reduced > 20%) in 77% of sampled eyes. In particular, IOP reduced at T2 and T3 with both MLT 1500 and 1000 without any significant differences (IOP reduction 22.9% vs. 17.3%, respectively, MLT1500 vs. MLT1000 at T2). The IOP returned to baseline values at T4 and T5 in both groups, with a reduction in topical medications administered from 2.5 ± 1.1 to 2.0 ± 1.2 to the 1500 mW group and from 2.4 ± 1.0 to 1.9 ± 1.0 to the 1000 mW group. At 1 h post-laser treatment, a transient IOP spike was registered among the MLT1500 group. There were no differences in CCT and ECC at any timepoint according to the laser powers. Conclusions: Over a 6-month follow-up period, 577 nm MLT at either 1500 or 1000 mW reduces IOP, enabling a stable reduction in the number of topical medications required for patients treated for POAG without any significant difference in terms of effectiveness and safety. Full article
(This article belongs to the Special Issue Glaucoma: Pathophysiology, Treatment and Progression)
►▼ Show Figures

Figure 1

12 pages, 1717 KiB  
Article
Long-Term Efficacy and Safety of Modified Canaloplasty Versus Trabeculectomy in Open-Angle Glaucoma
by Julia V. Stingl, Felix M. Wagner, Sarah Liebezeit, Raphael Baumgartner, Helene Spät, Alexander K. Schuster, Verena Prokosch, Franz Grehn and Esther M. Hoffmann
Life 2023, 13(2), 516; https://doi.org/10.3390/life13020516 - 13 Feb 2023
Cited by 2 | Viewed by 1994
Abstract
Background: To evaluate the long-term efficacy and safety of modified canaloplasty versus trabeculectomy in open-angle glaucoma. Methods: In total, 210 subjects with open-angle glaucoma were included. 70 were treated with Mitomycin C-augmented modified canaloplasty with enhanced subconjunctival filtration and 140 with Mitomycin C-augmented [...] Read more.
Background: To evaluate the long-term efficacy and safety of modified canaloplasty versus trabeculectomy in open-angle glaucoma. Methods: In total, 210 subjects with open-angle glaucoma were included. 70 were treated with Mitomycin C-augmented modified canaloplasty with enhanced subconjunctival filtration and 140 with Mitomycin C-augmented trabeculectomy. Cases were matched 1:2 by sex and age. Results: In canaloplasty and trabeculectomy groups, 61.4% and 57.9% of participants were female. Mean age was 60.0 ± 13.9 and 63.0 ± 12.2 years, median follow-up time was 4.6 [IQR 4.3, 5.05] years and 5.8 [IQR 5.4, 6.3]. Strict success was achieved in 20.0% and 56.4%, complete success in 24.3% and 66.4%, and qualified success in 34.3% and 73.6% (each p < 0.001). Kaplan–Meier survival analysis showed a better survival probability for trabeculectomy than for canaloplasty (p < 0.001) and Cox regression analysis revealed an HR of 6.03 (95%-CI 3.66, 9.93, p < 0.001) after canaloplasty. Trabeculectomy showed superiority in terms of IOP decrease (9.2 ± 7.9 mmHg vs. 13.7 ± 10.4 mmHg, p = 0.002), use of AGM (50.0% vs. 10.7%, p < 0.001), and the number of revision surgeries (41.4% vs. 21.4%, p = 0.004). Occurrence of complications was similar in both groups (14.5% vs. 7.5%, p = 0.19). Conclusions: Trabeculectomy showed superiority in efficacy and equality in safety compared to modified canaloplasty. Full article
(This article belongs to the Special Issue Glaucoma: Pathophysiology, Treatment and Progression)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop